Companies 0 See All
Hedge Funds 0 See All
Insiders 0 See All
Institutional Investors 0 See All
Click here to see all results for
Home > Insider Trading > Filing (0001683168-23-002856)

Filing Details

Accession Number:
0001683168-23-002856
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-05-02 19:44:05
Reporting Period:
2023-05-01
Accepted Time:
2023-05-02 19:44:05
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
704562 Avid Bioservices Inc. CDMO Pharmaceutical Preparations (2834) 953698422
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1552642 R Mark Ziebell 14191 Myford Road
Tustin CA 92780		 V. P., General Counsel No Yes No No
Reported Non-Derivative Transactions
Show Other Fields >>
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock, $0.001 Par Value Acquisiton 2023-05-01 25,000 $9.87 65,119 No 4 M Direct
Common Stock, $0.001 Par Value Disposition 2023-05-01 25,000 $17.91 40,119 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Show Other Fields >>
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Disposition 2023-05-01 25,000 $0.00 25,000 $9.87
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
214,145 2023-05-06 No 4 M Direct
Footnotes
  1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 17, 2022.
  2. Represents a weighted average sales price per share. These shares were sold at prices ranging from $17.54 to $18.25. The Reporting Person has provided to the Issuer, and hereby undertakes to provide the SEC staff or a security holder of the Issuer, upon request, information regarding the number of shares sold at each respective price within the range set forth in this footnote.
  3. Stock option granted to the reporting person on May 6, 2013 vested in eight (8) equal quarterly installments and was fully-vested as of May 6, 2015.